The One Stock You Must Watch
An industry-shattering disruption is coming - this microcap is at the heart of it.
Click for ticker & full details
Matthew W. Foehr, insider at Ligand Pharmaceuticals

Matthew W. Foehr Insider Information

Matthew W. Foehr, has been our President and Chief Operating Officer since January 2015. Prior to that time, Mr. Foehr served as our Executive Vice President and Chief Operating Officer since 2011, and has more than 20 years of experience managing global research and development programs. Prior to joining our company in 2011, he was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GlaxoSmithKline (GSK). Following GSK’s $3.6 billion acquisition of Stiefel in 2009, Mr. Foehr led the R&D integration of Stiefel into GSK. At Stiefel Laboratories, Inc., Mr. Foehr served as Senior Vice President of Global R&D Operations, Senior Vice President of Product Development & Support, and Vice President of Global Supply Chain Technical Services. Prior to Stiefel, Mr. Foehr held various executive roles at Connetics Corporation including Senior Vice President of Technical Operations and Vice President of Manufacturing. Mr. Foehr serves on the Board of Directors of Viking Therapeutics, Inc., a publicly-traded biotechnology company and served as a director of Ritter Pharmaceuticals, Inc. from February 2015 until its merger with Qualigen Therapeutics, Inc. in May 2020. Mr. Foehr is the author of multiple scientific publications and is named on numerous U.S. patents. He received his B.S. degree in biology from Santa Clara University.

What is Matthew W. Foehr's net worth?

The estimated net worth of Matthew W. Foehr is at least $15.03 million as of May 13th, 2022. Mr. Foehr owns 173,354 shares of Ligand Pharmaceuticals stock worth more than $15,034,992 as of May 16th. This net worth evaluation does not reflect any other investments that Mr. Foehr may own. Additionally, Mr. Foehr receives a salary of $909,000.00 as COO at Ligand Pharmaceuticals. Learn More about Matthew W. Foehr's net worth.

How old is Matthew W. Foehr?

Mr. Foehr is currently 49 years old. There are 4 older executives and no younger executives at Ligand Pharmaceuticals. The oldest executive at Ligand Pharmaceuticals is Mr. Charles S. Berkman J.D., Sr. VP, Gen. Counsel & Sec., who is 53 years old. Learn More on Matthew W. Foehr's age.

What is Matthew W. Foehr's salary?

As the COO of Ligand Pharmaceuticals Incorporated, Mr. Foehr earns $909,000.00 per year. The highest earning executive at Ligand Pharmaceuticals is Mr. John L. Higgins, CEO & Exec. Director, who commands a salary of $1,230,000.00 per year. Learn More on Matthew W. Foehr's salary.

How do I contact Matthew W. Foehr?

The corporate mailing address for Mr. Foehr and other Ligand Pharmaceuticals executives is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. Ligand Pharmaceuticals can also be reached via phone at (858) 550-7500 and via email at [email protected] Learn More on Matthew W. Foehr's contact information.

Has Matthew W. Foehr been buying or selling shares of Ligand Pharmaceuticals?

In the last ninety days, Matthew W. Foehr has bought $206,900.00 in shares of Ligand Pharmaceuticals stock. Most recently, on Friday, May 13th, Matthew W. Foehr bought 2,500 shares of Ligand Pharmaceuticals stock. The stock was acquired at an average cost of $82.76 per share, with a total value of $206,900.00. Following the completion of the transaction, the chief operating officer now directly owns 173,354 shares of the company's stock, valued at $14,346,777.04. Learn More on Matthew W. Foehr's trading history.

Who are Ligand Pharmaceuticals' active insiders?

Ligand Pharmaceuticals' insider roster includes Matthew Foehr (COO), and John Higgins (CEO). Learn More on Ligand Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Ligand Pharmaceuticals?

During the last year, Ligand Pharmaceuticals insiders bought shares 1 times. They purchased a total of 2,500 shares worth more than $206,900.00. During the last year, insiders at the biotechnology company sold shares 4 times. They sold a total of 23,908 shares worth more than $3,363,464.96. The most recent insider tranaction occured on May, 13th when COO Matthew W Foehr bought 2,500 shares worth more than $206,900.00. Insiders at Ligand Pharmaceuticals own 9.7 % of the company. Learn More about insider trades at Ligand Pharmaceuticals.

Information on this page was last updated on 5/13/2022.

Matthew W. Foehr Insider Trading History at Ligand Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/13/2022Buy2,500$82.76$206,900.00173,354View SEC Filing Icon  
11/11/2021Sell11,160$163.02$1,819,303.20View SEC Filing Icon  
8/4/2021Sell8,840$109.67$969,482.80173,195View SEC Filing Icon  
2/4/2021Sell44,547$176.86$7,878,582.42167,198View SEC Filing Icon  
8/24/2020Sell78$110.89$8,649.42155,413View SEC Filing Icon  
8/21/2020Sell7,225$112.88$815,558.00155,413View SEC Filing Icon  
2/27/2020Buy7,225$14.47$104,545.75160,968View SEC Filing Icon  
2/27/2020Buy1,706$21.92$37,395.52155,449View SEC Filing Icon  
2/27/2020Sell7,225$110.00$794,750.00160,968View SEC Filing Icon  
2/15/2020Sell869$97.23$84,492.87155,360View SEC Filing Icon  
2/15/2020Sell447$97.23$43,461.81154,913View SEC Filing Icon  
2/15/2020Sell1,170$97.23$113,759.10153,743View SEC Filing Icon  
2/14/2020Buy7,225$14.47$104,545.75163,454View SEC Filing Icon  
2/14/2020Sell7,225$95.84$692,444.00148,833View SEC Filing Icon  
2/13/2020Buy496$21.92$10,872.32148,833View SEC Filing Icon  
2/13/2020Buy7,396$0.00$0.00156,229View SEC Filing Icon  
10/1/2018Sell12,000$273.88$3,286,560.00105,388View SEC Filing Icon  
9/4/2018Sell12,000$255.01$3,060,120.00103,300View SEC Filing Icon  
5/10/2018Sell8,881$167.63$1,488,722.03110,082View SEC Filing Icon  
2/23/2018Sell5,444$152.98$832,823.1295,835View SEC Filing Icon  
8/9/2017Sell6,100$127.51$777,811.00101,020View SEC Filing Icon  
5/12/2017Sell5,621$112.20$630,676.2098,341View SEC Filing Icon  
3/2/2017Sell6,879$103.39$711,219.8197,599View SEC Filing Icon  
3/17/2016Sell6,400$96.70$618,880.0083,062View SEC Filing Icon  
6/26/2015Sell12,500$100.97$1,262,125.00View SEC Filing Icon  
6/22/2015Sell23,046$96.45$2,222,786.70View SEC Filing Icon  
6/28/2013Buy1,059$17.36$18,384.24View SEC Filing Icon  
See Full Table

Matthew W. Foehr Buying and Selling Activity at Ligand Pharmaceuticals

This chart shows Matthew W Foehr's buying and selling at Ligand Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ligand Pharmaceuticals Company Overview

Ligand Pharmaceuticals logo
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
Read More

Today's Range

Now: $86.73
Low: $84.03
High: $87.63

50 Day Range

MA: $103.05
Low: $78.68
High: $120.80

2 Week Range

Now: $86.73
Low: $77.80
High: $169.98

Volume

134,855 shs

Average Volume

163,104 shs

Market Capitalization

$1.46 billion

P/E Ratio

62.85

Dividend Yield

N/A

Beta

1.22
Bargain in Today's Market (SHOCKING)
This "World's Most Admired" company's stock would be a bargain at $50...Today it's just $2! Plus... a key May 12 announcement could send it ROCKETING skyward...

Click Here Now (Before It's Too Late!)
>>>